In the press
Pre-clinical Biotech Development Opportunity Video
Pre-clinical Biotech Development Opportunity Video
Related Press
Leading Korean VC partners with USA’s Orange Grove
Orange Grove Bio, a USA-based pre-clinical drug investment and development firm, and SV Investment, a South Korea-based venture capital and private equity firm, today announced the establishment of a new partnership through which the companies will collaborate on jointly sourcing and developing novel therapeutics in the USA and Korea. As priority partners, the companies will cultivate the US and Korean biotech landscape through technology licensing and company creation in their respective geographic areas.
Under terms of the partnership, SV Investment will leverage its relationships with biotech companies and academic institutions in Korea to identify licensing opportunities for promising early-stage research in the area of drug development. As part of the agreement, Marc Appel, chief executive of Orange Grove, will join SV Investment as a venture partner and will play a key role in evaluating the licensing opportunities that are identified at Korean biotech companies and universities. As appropriate, Orange Grove will work to license these technologies as a basis for life science company creation in the USA, with SV Investment serving as an early-stage investor in the companies.
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend… Continue reading Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area The following excerpt was taken from Cincinnati Enquirer — continue reading here. Orange Grove Bio, a venture capital firm that invests mainly in therapeutic drug companies, is moving its headquarters from the New York City “Orange Grove Bio, a venture capital firm that invests… Continue reading Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry
Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry We are excited to announce our portfolio company, Ipinovyxbio‘s, launch! The following was taken from Fierce Biotech–read it here or continue below! “With a focus on autoimmune and inflammatory diseases, IpiNovyx Bio closed a $10 million seed financing round” “Eli Lilly is among the… Continue reading Eli Lilly-backed IpiNovyx Bio emerges with $10M for 2023 clinical entry
IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform
IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform The following excerpt was taken from Trialsitenews — continue reading here. IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform “New York-based IpiNovyx Bio announced the closing of a $10 million seed financing round. The financing was led… Continue reading IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform
1819 Innovation Hub tenant inks key partnership with Korea VC firm
1819 Innovation Hub tenant inks key partnership with Korea VC firm The following excerpt was taken from TechOhio– continue reading here. A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration A biotech firm that moved its headquarters from New York to Cincinnati in… Continue reading 1819 Innovation Hub tenant inks key partnership with Korea VC firm
IpiNovyx Bio closes $10 million seed financing round
IpiNovyx Bio closes $10 million seed financing round The below is an excerpt taken from EndPoints News about our portfolio company, Ipinovyx Bio. The following excerpt was taken from EndPonts News — continue reading here. “With a focus on autoimmune and inflammatory diseases, IpiNovyx Bio closed a $10 million seed financing round “With a focus… Continue reading IpiNovyx Bio closes $10 million seed financing round
New Partnership Continues Pitt’s Turn Toward Commercializing Research
New Partnership Continues Pitt’s Turn Toward Commercializing Research The following excerpt was taken from Pittsburgh Post-Gazette — continue reading here. An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies “An Ohio drug investment and development firm is partnering with the University of Pittsburgh to commercialize therapies targeting… Continue reading New Partnership Continues Pitt’s Turn Toward Commercializing Research
Orange Grove Bio and Cincinnati Children’s Hospital Medical Center Establish Collaboration
Orange Grove Bio, a preclinical drug investment and development firm, and Cincinnati